Novel gastroretentive dosage forms: Evaluation of gastroretentivity and its effect on levodopa absorption in humans

Pharmaceutical Research

Volumn 20, Issue 9, 2003, Pages 1466-1473

  Klausner, Eytan A ^a   Lavy, Eran ^b   Barta, Miklos ^c   Cserepes, Eva ^c   Friedman, Michael ^a   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c NATIONAL MEDICAL CENTER   (Hungary)

Author keywords

Controlled release; Drug delivery; Gastroretentive; Healthy volunteers; Levodopa

Indexed keywords

CARBIDOPA PLUS LEVODOPA; EUDRAGIT; GELATIN; LEVODOPA;

ADULT; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG SCREENING; FEMALE; GASTRORETENTIVE DOSAGE FORM; GASTROSCOPY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAL; MOLECULAR MECHANICS; NORMAL HUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIOLOGY; RIGIDITY; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTIPARKINSON AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; GASTRIC EMPTYING; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; LEVODOPA; MALE; SOLUBILITY; STOMACH; TIME FACTORS;

EID: 0141455046     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025770530084     Document Type: Article

References (30)

1. S.-J. Hwang, H. Park, and K. Park. Gastric retentive drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 15:243-284 (1998).
2. A. Rubinstein and D. R. Friend. Specific delivery to the gastrointestinal tract. In A. J. Domb (ed.), Polymeric Site-Specific Pharmacotherapy, John Wiley & Sons Ltd, Chichester, 1994, pp. 267-313.
3. W. S. W. Shalaby and K. Park. Biochemical and mechanical characterization of enzyme-digestible hydrogels. Pharm. Res. 7:816-823 (1990).
4. J. Chen and K. Park. Synthesis and characterization of superporous hydrogel composites. J. Control. Release 65:73-82 (2000).
5. El-Gibaly. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: Comparison with non-floating chitosan microspheres. Int. J. Pharm. 249:7-21 (2002).
6. W. S. W. Shalaby, W. E. Blevins, and K. Park. In vitro and in vivo studies of enzyme-digestible hydrogels for oral drug delivery. J. Control. Release 19:131-144 (1992).
7. V. Rosenberger, M. Dahan, Y. Imakov, E. I. Lerner, and M. Fleshner-Barak. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition, Int. Application WO0200213, 2002.
8. N. Ozdemir, S. Ordu, and Y. Ozkan. Studies of floating dosage forms of furosemide: In vitro and in vivo evaluations of bilayer tablet formulations. Drug Dev. Ind. Pharm. 26:857-866 (2000).
9. J. A. Fix, R. Cargill, and K. Engle. Controlled gastric emptying. III. Gastric residence time of a nondisintegrating geometric shape in human volunteers. Pharm. Res. 10:1087-1089 (1993).
10. W. Sawicki. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. Eur. J. Pharm. Biopharm. 53: 29-35 (2002).
11. D. Deleu, M. G. Northway, and Y. Hanssens. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacokinet. 41:261-309 (2002).
12. A. Hoffman. Pharmacodynamic aspects of sustained release preparations. Adv. Drug Deliv. Rev. 33:185-199 (1998).
13. E. A. Klausner, S. Eyal, E. Lavy, M. Friedman, and A. Hoffman. Novel levodopa gastroretentive dosage form: In vivo evaluation in dogs. J. Control. Release 88:117-126 (2003).
14. R. E. Dempski, E. C. Scholtz, E. R. Oberholtzer, and K. C. Yeh. Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 39(suppl 2):20-24 (1989).
15. E. C. Wolters and H. J. M. Tesselaar. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. J. Neurol. 243:235-240 (1996).
16. A. Hoffman and D. Stepensky. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit. Rev. Ther. Drug Carrier Syst. 16:571-639 (1999).
17. W. Erni and K. Held. The hydrodynamically balanced system: A novel principle of controlled drug release. Eur. Neurol. 27(suppl 1):21-27 (1987).
18. J. Siegfried. Therapeutic value of Madopar HBS: Judgment after 2 years experience. Eur. Neurol. 27(suppl 1):98-104 (1987).
19. A. Grahnen, S.-A. Eckernas, C. Collin, A. Ling-Andersson, G. Tiger, and M. Nilsson. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. Eur. Neurol. 32:343-348 (1992).
20. E. A. Klausner. Design and characterization of novel gastroretentive dosage forms for widening the therapeutic potential of narrow absorption window drugs, The Hebrew University of Jerusalem, PhD Thesis, 2002.
21. M. Friedman, E. Klausner, E. Lavy, and A. Hoffman. Gastroretentive controlled release pharmaceutical dosage forms, Int. Application WO0137812, 2001.
22. E. A. Klausner, E. Lavy, D. Stepensky, M. Friedman, and A. Hoffman. Novel gastroretentive dosage forms: Evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm. Res. 19:1516-1523 (2002).
23. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
24. D. C. Titus, T. F. August, K. C. Yeh, R. Eisenhandler, W. F. Bayne, and D. G. Musson. Simultaneous high-performance liquid chromatographic analysis of carbidopa, levodopa and 3-0-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection. J. Chromatograph. 534:87-100 (1990).
25. M. Bialer, A. Yacobi, D. Moros, B. Levitt, J.-M. Houle, and M. S. Munsaka. Criteria to assess in vivo performance and bioequivalence of generic controlled-release (CR) formulations of carbamazepine. Epilepsia 39:513-519 (1998).
26. J. Chen, W. E. Blevins, H. Park, and K. Park. Gastric retention properties of superporous hydrogel composites. J. Control. Release 64:39-51 (2000).
27. E. A. Klausner, E. Lavy, M. Friedman and A. Hoffman. Expandable gastroretentive dosage forms. J. Control. Release 20:143-162 (2003).
28. W. S. W. Shalaby, W. E. Blevins, and K. Park. Use of ultrasound imaging and fluoroscopic imaging to study gastric retention of enzyme-digestible hydrogels. Biomaterials 13:289-296 (1992).
29. R. Cargill, L. J. Caldwell, K. Engle, J. A. Fix, P. A. Porter, and C. R. Gardner. Controlled gastric emptying. I. Effects of physical properties on gastric residence times of nondisintegrating geometric shapes in beagle dogs. Pharm. Res. 5:533-536 (1988).
30. K. C. Yeh, T. F. August, D. F. Bush, K. C. Lasseter, D. G. Musson, S. Schwartz, M. E. Smith, and D. C. Titus. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 39(suppl 2):25-38 (1989).